GSK announces preliminary results from phase III trial of AREXVY

GSK announced positive preliminary results from its phase III trial evaluating the immune response and safety of AREXVY in adults aged 50 to 59, including those at increased risk of respiratory syncytial virus, RSV, lower respiratory tract disease, LRTD, due to certain underlying medical conditions. These results will be presented at the US Centers for Disease Control and Prevention’s, CDC, Advisory Committee on Immunization Practices, ACIP, meeting on October 25, 2023. This vaccine is currently approved in the US for active immunization for the prevention of RSV-LRTD in adults 60 years of age and older. It is also approved in Europe, Japan, and several other countries. Tony Wood, Chief Scientific Officer, GSK, said: “This trial reinforces our confidence in our RSV vaccine’s ability to help protect adults aged 50 to 59 at increased risk for RSV-LRTD. We will submit these data for regulatory review as quickly as possible with the goal of offering adults in this age group the option of a vaccine for the first time.”